Industrial conglomerate 3M Company is partnering with the Massachusetts Institute of Technology to develop a cheaper, quicker COVID-19 test. 

Right now, test results can take anywhere from a few hours to a week. Quest Diagnostics, for instance, said the average turnaround time at its labs is currently seven days. 

3M's new test would function more like a pregnancy strip, a rapid paper-based test that could be mass-produced and quickly distributed at the point of care.  

"In terms of patient experience, what we're looking to do is create that low-cost, highly-accurate, simple-to-use test that would be accessible to a lot of people," Dr. John Banovetz, chief technology officer for 3M, told Cheddar. 

The antigen-based test, which looks at proteins on the virus, would offer a "preliminary view" of a patient's coronavirus status — though ideally, patients would follow up with a doctor, he added.  

"Our goal would be a point-of-care test, so maybe it's taken in a doctor's office. Maybe you pick it up at the pharmacy," Banovetz said. 

The goal is to start producing tests by the end of summer or early fall. Once manufacturing is rolling, 3M could produce millions of tests per day, according to the company. 

As cases surge across the country and many anticipate a second wave in states where the infection rate has dropped off, calls for more testing are growing. 

More than 41 million tests have been reported to the CDC, with a 9 percent positivity rate, but the U.S. continues to lag behind other countries by some measures.  

In the meantime, the Trump administration is relying on the private sector to meet the demand for tests, putting pressure on companies such as 3M to come up with a solution. 

"We're going as quick as we can right now," he said. "Our focus is trying to get that accuracy up and in a way that we know that we can mass-produce it. That's really where 3M can help contribute to this, our ability to be able to commercialize and bring to market new ideas and innovations." 

Share:
More In Science
One Good Thing: All 14 Patients in Experimental Trial Saw Cancer Go Into Remission
What's being called an unprecedented breakthrough in cancer treatment recently completed a small trial at New York City's Memorial Sloan Kettering in 14 rectal cancer patients. The experimental trial with the drug dostarlimab resulted in 100 percent remission in all candidates, precluding the need for chemotherapy or surgery. Cheddar News anchor Hena Doba dives into this hopeful story.
A New Plant-Based Way to Quit Smoking
John Bencich, CEO of Achieve Life Sciences, joins Cheddar Innovates to discuss a new plant-based compound that's being used to fight nicotine addiction.
Plant-Based Way to Quit Smoking; Innovation in Stroke Therapy
On this episode of Cheddar Innovates: CEO of Achieve Life Sciences discusses a new plant-based compound that's being used to fight nicotine addiction; President & CEO OF DiaMedica Therapeutics explains a new ischemic stroke treatment option that expands the window for effective therapy for stroke patients; Cheddar gets a look at Curiosity Stream's 'Asteroid Rush.'
Load More